Agreement will Bring Alnylam’s Proprietary siRNA Technology to Bear on Liver Target Identified by Novartis Researchers –
– Alnylam and Novartis have Agreed to Collaborate on Discovery and Development of siRNA-based Targeted Therapy to Restore Functional Liver Cells in Patients with End-Stage Liver Diseases --
– Collaboration Aims to Develop Liver-Targeted Therapy as a Potential Alternative to Transplantation for Patients Experiencing Liver Failure –
https://finance.yahoo.com/news/alnylam-announces-collaboration-novartis-explore-123000768.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.